Cell-derived viral vaccines with low levels of residual cell DNA by betapropiolactone treatment

Details for Australian Patent Application No. 2006310171 (hide)

Owner Novartis Vaccines and Diagnostics GmbH & Co KG

Inventors Kost, Holger; Gregersen, Jens-Peter

Agent FB Rice

Pub. Number AU-B-2006310171

PCT Pub. Number WO2007/052163

Priority 60/732,786 01.11.05 US

Filing date 1 November 2006

Wipo publication date 10 May 2007

Acceptance publication date 17 February 2011

International Classifications

A61K 39/12 (2006.01) Medicinal preparations containing antigens or antibodies - Viral antigens

A61K 39/145 (2006.01) Medicinal preparations containing antigens or antibodies - Orthomyxoviridae, e.g. influenza virus

Event Publications

22 May 2008 PCT application entered the National Phase

  PCT publication WO2007/052163 Priority application(s): WO2007/052163

17 February 2011 Application Accepted

  Published as AU-B-2006310171

16 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006310173-A lentiviral vector-based vaccine

2006310170-Concentration of fatty acid alkyl esters by enzymatic reactions with glycerol